Why is Mankind Pharma falling/rising?

As of 20-Aug, Mankind Pharma Ltd's stock price is currently at 2,505.60, reflecting an increase of 14.15, or 0.57%. The stock has been gaining for the last three days, with a total return of 1.48% during this period. Despite this recent uptick, the stock has underperformed over the past month, showing a decline of 5.55%, while it has outperformed the sector today by 0.99%. The stock's performance is supported by strong fundamentals, including a high return on equity of 17.21% and a low debt to EBITDA ratio of 0.69, indicating efficient management and a solid ability to service debt. However, there has been a decline in investor participation, with delivery volume decreasing by 3.33% compared to the five-day average.
In the broader market context, Mankind Pharma's short-term performance has lagged behind the benchmark Sensex, which has increased by 1.64% over the past week. While the stock has shown some resilience with a recent upward movement, its year-to-date performance remains negative at -12.90%, contrasting sharply with the Sensex's positive return of 4.76% during the same period. This disparity highlights the challenges the stock faces despite its strong management efficiency and institutional support, which may not be enough to offset broader market trends and investor sentiment.